Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection

Table 7 Prognostic factors for overall survival and relapse-free survival in the hepatocellular carcinoma patients with renal dysfunction

Variable (RD patients)	Univariate analysis (OS)		Multivariate analysis (OS)		Univariate analysis (RFS)		Multivariate analysis (RFS)
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Age > 60 yr	2.33 (1.14-5.63)	< 0.05	3.85 (0.81-22.53)	0.092	2.08 (1.01-5.01)	< 0.05	0.98 (0.26-4.76)	0.978
Male	1.37 (0.73-2.82)	0.371			1.66 (0.88-3.48)	0.122
HBV+	1.00 (0.56-1.67)	0.995			1.02 (0.57-1.73)	0.947
HCV+	0.97 (0.60-1.52)	0.899			1.03 (0.64-1.63)	0.889
NBNC	1.03 (0.66-1.60)	0.898			0.96 (0.61-1.50)	0.849
Child-Pugh grade B	2.16 (0.12-10.17)	0.44			0.90 (0.05-4.13)	0.919
Plt < 13.8	0.88 (0.54-1.40)	0.598			0.76 (0.46-1.22)	0.257
PT < 80	0.89 (0.47-1.57)	0.706			1.05 (0.57-1.81)	0.858
Alb < 4.0	1.25 (0.80-1.95)	0.321			1.23 (0.78-1.92)	0.376
T-bil > 1.2	0.87 (0.30-2.01)	0.772			1.03 (0.40-2.18)	0.95
AST > 38	1.15 (0.74-1.79)	0.534			1.31 (0.85-2.05)	0.223
ALT > 44	0.71 (0.43-1.14)	0.162			1.21 (0.76-1.90)	0.421
ChE < 168	2.40 (1.22-4.32)	< 0.01	1.06 (0.31-3.15)	0.921	3.15 (1.59-5.79)	< 0.01	2.21 (0.17-1.35)	0.147
ICGR15 > 15	0.94 (0.60-1.48)	0.800			1.36 (0.87-2.14)	0.176
HbA1c > 5.6	1.49 (0.87-2.55)	0.145			0.94 (0.57-1.56)	0.823
AFP > 10	1.51 (0.97-2.39)	0.068			2.07 (1.32-3.28)	< 0.01	0.79 (0.29-2.03)	0.634
AFP-L3 > 10	2.97 (1.74-5.01)	< 0.0001	2.57 (0.99-6.70)	0.051	2.21 (1.33-3.59)	< 0.01	2.22 (0.87-5.98)	0.095
PIVKA-II > 40	1.85 (1.17-3.00)	< 0.01	2.57 (0.64-11.50)	0.186	1.53 (0.97-2.46)	0.067
Operative time > Ave	0.96 (0.62-1.50)	0.868			0.98 (0.62-1.53)	0.916
Blood loss > Ave	1.31 (0.78-2.13)	0.282			1.17 (0.70-1.89)	0.533
Anatomical resection	1.06 (0.64-1.85)	0.833			0.79 (0.48-1.37)	0.391
Resected liver weight > Ave	2.05 (1.18-3.44)	< 0.01	0.99 (0.37-2.66)	0.978	1.53 (0.87-2.59)	0.137
Tumor size > Ave	1.94 (1.18-3.10)	< 0.01	1.06 (0.33-3.30)	0.918	1.88 (1.14-3.04)	< 0.05	1.86 (0.63-5.40)	0.258
Tumor number > 1	2.13 (1.30-3.45)	< 0.01	2.44 (1.04-5.75)	< 0.05	3.46 (2.04-5.85)	< 0.0001	3.77 (1.61-8.97)	< 0.01
Pathological grade (mod-por)	1.23 (0.70-2.34)	0.505			1.32 (0.76-2.47)	0.337
Vascular invasion (Vp+, Vv+)	4.92 (2.21-9.84)	< 0.0001	1.88 (0.61-5.14)	0.26	4.08 (1.86-8.00)	< 0.01	1.89 (0.70-4.60)	0.198
Liver fibrosis score 3, 4	1.29 (0.80-2.03)	0.278			1.37 (0.86-2.16)	0.186

OS: Overall survival; RFS: Recurrence-free survival; HR: Hazard ratio; CI: Confidence interval; RD: Renal dysfunction; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NBNC: Non-hepatitis B virus or hepatitis C virus; Plt: Platelet counts; PT: Prothrombin time; Alb: Serum albumin; T-bil: Total bilirubin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ChE: Choline esterase; ICGR15: Indocyanine green rate at 15 min; HbA1c: Hemoglobin A1c; BUN: Blood urea nitrogen; Cr: Creatinine; AFP: Alpha-fetoprotein; AFP-L3: Alpha-fetoprotein isoform, lectin affinity; PIVKA-II: Protein-induced vitamin K absence-II; Ave: Average; Mod: Moderately differentiated; por: Poorly differentiated; Vp: Portal vein invasion; Vv: Hepatic vein invasion.